Mirecule Inc. has entered into a strategic collaboration and exclusive license agreement with Sanofi SA to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Praetego Inc. has been awarded a US$2.5 million phase II Small Business Technology Transfer (STTR) award from the National Institute on Aging (NIA) to its advance lead candidate, PTG-630, for Alzheimer's disease.

Cerecin Inc. has successfully closed the first tranche of a series IIB financing with investors from South Korea, with SK Securities Co. Ltd. and KNT Investment LLC leading the round.

Analysts were upbeat about positive results from Eisai Co Ltd. and Biogen Inc.’s phase III confirmatory Clarity Alzheimer’s disease (AD) trial of lecanemab that met both primary and secondary endpoints, and most agreed that the data should be enough to gain FDA approval for mild cognitive impairment due to AD.

For a long time, α2-adrenoceptor antagonists have been successfully used as adjunct therapy to improve pharmacotherapy of antipsychotics, antidepressants or anti-parkinsonian drugs.

Leucine-rich repeat kinase 2 (LRRK2) mutations adversely impair multiple physiological processes, and gain-of-function mutations in the LRRK2 gene are common in familial forms of Parkinson’s disease (PD).

Cerecin Inc. has successfully closed the first tranche of a series IIB financing with investors from South Korea, with SK Securities Co. Ltd. and KNT Investment LLC leading the round. Proceeds from the financing, of undisclosed value, will help the company advance clinical studies of its CER-0001 (tricaprilin) in migraine and infantile spasm.

Cell cycle-associated protein 1 (CAPRIN1) is an ubiquitously expressed protein, the levels of which are usually high in tissues with an elevated cell turnover; it is also abundant in the brain, where it regulates the transport and translation of synaptic protein mRNA.